Subsequently, we conducted a comprehensive prognostic analysis of six tumors with significant overexpression of AKR1B10 in pan-cancer studies through the GSCA database, and the results show that although AKR1B10 exhibits significant expression differences in various tumors, it is only significantly related to poor survival in liver cancer patients, highlighting the importance of AKR1B10 as a prognostic biomarker for HCC. This evidence concerns the gene AKR1B10 and cancer.